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Catherine K. Chang, MD, Alyson L. Waterman, MD, MPH, Scott A. Berceli, MD, PhD, and
Thomas S. Huber, MD, PhD, Gainesville, Fla
Objective: Patients presenting with occluded aortobifemoral (ABF) bypass grafts are managed with a variety of techniques.
Redo ABF (rABF) bypass procedures are infrequently performed because of concerns about procedural complexity and
morbidity. The purpose of this analysis was to compare midterm results of rABF bypass with those of primary ABF
(pABF) bypass for aortoiliac occlusive disease to determine if there are signiﬁcant differences in outcomes.
Methods: A retrospective review was performed of all patients undergoing ABF bypass for occlusive disease between
January 2002 and March 2012. A total of 19 patients underwent rABF bypass and 194 received pABF bypass during that
period. Data for an indication- and comorbidity-matched case-control cohort of 19 elective pABF bypass patients were
collected for comparison to the rABF bypass group. Primary end points included rate of major complications as well as
30-day and all-cause mortality. Secondary end points were amputation-free survival and freedom frommajor adverse limb
events.
Results: The rABF bypass patients more frequently underwent prior extra-anatomic or lower extremity bypass operations
compared with pABF bypass patients (P [ .02); however, no difference was found in the incidence of prior failed
endovascular iliac intervention (P [ .4). By design, indications for the rABF and pABF bypass groups were the same
(claudication, n [ 6/6 [31.6%]; P [ 1; critical limb ischemia, n [ 13/13 [78.4%]; P [ 1). Aortic access was more
frequently by retroperitoneal exposure in the rABF bypass group (n[ 13 vs n[ 1; P < .0001), and a signiﬁcantly higher
proportion of the rABF bypass patients required concomitant infrainguinal bypass or intraprocedural adjuncts such as
profundaplasty (n[ 14 vs n[ 5; P[ .01). The rABF bypass patients experienced greater blood loss (1097 6 983 mL vs
580 6 457 mL; P[ .02), received more intraoperative ﬂuids (3400 6 1422 mL vs 2279 6 993 mL; P[ .01), and had
longer overall procedure times (408 6 102 minutes vs 270 6 48 minutes; P < .0001). Length of stay (days 6 standard
deviation) was similar (pABF bypass, 11.2 6 10.4; rABF bypass, 9.1 6 4.5; P[ .7), and no 30-day or in-hospital deaths
occurred in either group. Similar rates of major complications occurred in the two groups (pABF bypass, n[ 6 [31.6%];
rABF bypass, n [ 4 [21.1%]; observed difference, 9.5%; 95% conﬁdence interval, L17.6% to 36.7%; P [ .7). Two-year
freedom from major adverse limb events (6standard error mean) was 82%6 9% vs 78%6 10% for pABF and rABF bypass
patients (log-rank, P[ .6). Two-year amputation-free survival was 90 6 9% vs 89 6 8% between pABF and rABF bypass
patients (P [ .5). Two-year survival was 91% 6 9% and 90% 6 9% for pABF and rABF bypass patients (P [ .8).
Conclusions: Patients undergoing rABF bypass have higher procedural complexity compared with pABF bypass as
evidenced by greater operative time, blood loss, and need for adjunctive procedures. However, similar perioperative
morbidity, mortality, and midterm survival occurred in comparison to pABF bypass patients. These results support a role
for rABF bypass in selected patients. (J Vasc Surg 2014;60:346-55.)The “gold standard” for management of complex aortoil-
iac occlusive disease (AIOD) is aortobifemoral (ABF) bypass
grafting, with 10-year primary patency exceeding 75% to
80%.1-3 However, 10% to 20% of patients experience some
form of graft failure, including limb stenosis, thrombosis,the Division of Vascular Surgery and Endovascular Therapy, Univer-
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://dx.doi.org/10.1016/j.jvs.2014.02.002infection, and degenerative pseudoaneurysm.4,5 A subset of
these patients (1%-3%)6 present with bilateral limb occlusion,
and the optimal treatment is unclear. Multiple remedial
choices exist to manage an occluded ABF bypass graft, such
as limb thrombectomy, axillobifemoral bypass, thoracobife-
moral bypass, or “redo” ABF (rABF) bypass. Several factors
inﬂuence surgical decision-making, including the patient’s
symptoms (eg, critical limb ischemia vs claudication),
comorbidities, distribution of occlusive disease, anticipated
complexity of an aortic reconstruction, durability of the
remedial choice, and the patient’s preference.
Major perioperative morbidity (10%-30%) and mortality
(1%-4%) rates of elective ABF bypass are well docu-
mented7-9; however, there are limited data on the outcome
of rABF bypass for AIOD, and early reports suggest that
there is prohibitive risk in performing these procedures.10,11
Because of these concerns, attempts to preserve the aortic
graft (eg, graft thrombectomy) and extra-anatomic recon-
struction are most frequently performed for ABF bypass
graft occlusion.12 These strategies have signiﬁcant merit in
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 2 Scali et al 347high-risk patients, but they may be inferior to in-line aortic
reconstruction with respect to patency and hemodynamic
impact.
The purpose of this report was to describe our experi-
ence with rABF bypass for management of AIOD and to
compare it with primary ABF (pABF) bypass to determine
if there are signiﬁcant differences in early and midterm
outcomes.
METHODS
Database and subjects. After approval from the Insti-
tutional Review Board (IRB #201300032), a retrospective
review was performed at the University of Florida to iden-
tify all patients undergoing open abdominal aortic surgery
(n ¼ 839) from January 2002 to January 2013. Patients
receiving operations for aneurysm or infection-related
indications were excluded. In addition, patients undergo-
ing remedial operations for degenerative anastomotic
pseudoaneurysm or axillofemoral bypass were not analyzed.
Aortofemoral or thoracofemoral bypass cases performed for
AIOD were further reviewed to determine which subjects
underwent a reoperative aortic procedure. The study
cohort is composed of 18 rABF bypass patients and an
additional patient receiving thoracobifemoral bypass after a
failed ABF bypass (n ¼ 19).
Case-control study design. To determine if rABF
bypass grafting leads to elevated perioperative risk of
morbidity and mortality, pABF bypass patients were
used as a reference group. The 19 rABF bypass patients
were analyzed to delineate parameters of mean age,
gender, body mass index, and surgical indication. A previ-
ously described Society for Vascular Surgery (SVS)
comorbidity score13 was calculated for each patient to
further improve matching accuracy ($8 ¼ high risk). A
control group of 19 patients matched for demographics,
comorbidity, and indication undergoing elective pABF
bypass grafting (all with TransAtlantic Inter-Society
Consensus II type D14 AIOD) during the same period
was subsequently identiﬁed and compared with the rABF
bypass patients. Speciﬁcally, once the rABF bypass cova-
riates were deﬁned, pABF bypass patients were selected on
the basis of age (within 610 years of the mean age of the
rABF bypass cohort), indication, and SVS comorbidity
score (within 61 of the mean SVS comorbidity score of
the rABF bypass cohort). The most recent pABF bypass
patients were reviewed, and ultimately 25 patients were
analyzed from 2010 to 2012, of whom 19 were found
who met selection criteria. The six patients not included
from the pABF bypass group were excluded because of
lack of matched indication (two) or low SVS comorbidity
score (four).
Data collection and deﬁnitions. Demographics,
comorbidities, previous vascular operations, noninvasive
vascular laboratory data, indications, postoperative
outcomes, and need for reintervention or amputation
were obtained through chart review. Operative records
were analyzed to record aortic access method, need for
adjunct procedures (deﬁned as any concomitant visceralor renal bypass, reimplantation or endarterectomy, profun-
daplasty, or infrainguinal bypass), conduit type and conﬁg-
uration, cross-clamp location and duration, operative time
(incision to dressing application), and blood loss.
Patient comorbidities were deﬁned as any prior history
of hypertension (any antihypertensive drug), coronary
artery disease (angina, coronary artery bypass, percuta-
neous angioplasty), chronic obstructive pulmonary disease
(smoking history >20 pack-years, abnormal pulmonary
function test results, medication), diabetes mellitus (oral
hypoglycemics, insulin), congestive heart failure (New
York Heart Association class II or greater), chronic renal
insufﬁciency (creatinine concentration $1.8 mg/dL or
dialysis dependence), dyslipidemia (chart history or medi-
cation), and cerebrovascular occlusive disease (transient
ischemic attack, stroke, carotid endarterectomy, angio-
plasty). Peripheral arterial occlusive disease severity was
graded on the basis of reporting guidelines.15 Graft patency
was determined by documentation of a femoral pulse on
examination and preservation of the ankle-brachial index
(ABI) during the follow-up interval.
Clinical practice. A majority of rABF bypass cases
(90%) were referred from other institutions after present-
ing with a failed pABF bypass graft. With the exception
of emergent cases (eg, acute limb ischemia), most sub-
jects underwent extensive preoperative evaluation. This
included cardiopulmonary testing, such as chest radio-
graphy, electrocardiography, and echocardiography, as
well as basic laboratory studies and ABI. Selected patients
received vein mapping or lower extremity arteriography if
infrainguinal bypass was anticipated to be needed to
achieve adequate revascularization. Pulmonary function
testing was obtained if a signiﬁcant history of chronic
obstructive pulmonary disease (more than two drugs,
inhaled or oral steroid use, or oxygen dependence) was
present. The surgeon’s discretion determined the need
for further risk stratiﬁcation, including cardiology referral
if functional capacity was <4 metabolic equivalents or an
abnormal ejection fraction was identiﬁed on echocardiog-
raphy. Preoperative imaging in all cases included an arte-
rial phase, thin-cut (#2 mm) contrasted computed
tomography angiogram. Choice of remedial strategy for a
failed ABF bypass graft is further highlighted in the
algorithm (Fig 1).
After operation, patients recovered in the surgical
intensive care unit (ICU) and subsequently were trans-
ferred to a dedicated cardiovascular nursing ward. The
individual surgeon’s discretion determined timing of care
transition and discharge. Postoperative surveillance
included follow-up at 1, 6, and 12 months and annually
thereafter, with physical examination and ABIs unless the
patient had concomitant infrainguinal bypass, in which
case duplex surveillance was obtained at 1, 3, 6, 9, and
12months and every 6months thereafter. Additional imag-
ing (eg, computed tomography angiography) was obtained
if the patient had$0.15 ABI decrease or change in clinical
status. The surgeon’s judgment determined timing, need,
and type of reintervention.
Fig 1. This decision algorithm depicts the philosophy that is applied in our practice to determine what remedial
strategy will be employed for patients presenting with an occluded aortobifemoral (ABF) bypass graft. ALI, Acute limb
ischemia; AxFem, axillofemoral; CLI, critical limb ischemia; LEB, lower extremity bypass; Thoracofem, thoracofemoral.
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retroperitoneal access. Aortic access in a majority (68.4%)
of rABF bypass patients was achieved by a retroperitoneal
approach through a curvilinear left posterolateral incision
extending from the midline halfway between the umbilicus
and the pubic bone to the eighth or ninth intercostal space.
Patients are placed in a right lateral decubitus position on a
bean bag with the kidney break centered between the ante-
rior superior iliac crest and caudal margin of the ribs. The
hips are left as ﬂat as possible to facilitate access to the
femoral vessels, and the chest/upper torso is rotated
approximately 30 degrees with the left shoulder elevated
and immobilized on an armrest (Fig 2, A).
After oblique muscle division, the plane posterior to
the left kidney is entered and the viscera are reﬂected to
the right. A ﬁxed retractor system is used to facilitate expo-
sure (eg, Bookwalter retractor; Codman & Shurtleff, Rayn-
ham, Mass). The lumbar vein is routinely divided to gain
exposure to the infrarenal aorta and serves as a marker
for the left renal artery. Depending on the patient’s body
habitus and need for adjunctive visceral or renal proce-
dures, the left crus of the diaphragm is divided to expose
the suprarenal aorta. Because of extensive scarring, it may
be difﬁcult or dangerous to attempt retroperitoneal tunnels
in the vicinity of the right iliac vessels, so we prefer to place
the right limb into a more anterior, preperitoneal position
coursing cephalad to the bladder. This tunnel is created by
bluntly dissecting in the preperitoneal plane with one hand
and deep to the inguinal ligament on the right with the
other hand (Fig 2, B).
Clamp application level is chosen on the basis of the
impression of the preoperative computed tomography angio-
gram, palpation of the aorta intraoperatively, and adequacyof aorta below the renal arteries but above the prior repair.
Most frequently, a suprarenal clamp position was employed
immediately above the renal arteries and an end-to-end
anastomosis with a collagen-impregnated double velour
prosthetic graft (Hemashield; Atrium, Hudson, NH) con-
structed after infrarenal aortic transection immediately above
the previous repair (Fig 2, C). In addition, if the patient had
previously undergone pABF bypass with an end-to-end
conﬁguration that was immediately below the renal arteries,
we have transected the existing graft and used a small ring of
residual graft in the new anastomosis. Irrespective of anasto-
motic reconstruction technique, the main body of the
conduit is left as long as possible, thereby providing maximal
graft length to facilitate access to the right femoral vessels.
The limbs of the graft are tunneled through the retroper-
itoneal space created by rotating the viscera to the patient’s
right. Alternatively, a femorofemoral bypass can be con-
structed if the preperitoneal space is scarred or difﬁculty is
encountered in creating the tunnels. The femoral anastomosis
is extended onto the profunda vessels, with concomitant pro-
fundaplasty or infrainguinal bypass frequently needing to be
performed.
Statistical analysis. Primary end points included 30-day
and in-hospital mortality and postoperative morbidity. Sec-
ondary end points were all-cause mortality, need for reinter-
vention, major adverse limb events [MALEs],16 and
amputation-free survival. Log-rank tests and Kaplan-Meier
product-limit estimates were performed to determine differ-
ences between the rABF and pABF bypass cohorts. Fisher
exact andMann-Whitney tests were used to compare nominal
and continuous categorical variables when appropriate. All
deaths were veriﬁed from the Social Security Death Index
Masterﬁle. The R-statistical software package (V.2.15.0;
Fig 2. A, Depiction of the patient positioning for redo aortobifemoral (ABF) bypass surgery through a left retro-
peritoneal aortic exposure. Note (inset) that the hips are left as ﬂat as possible to allow access to the right femoral
incision, and the patient is placed over the kidney break to facilitate maximal separation of the iliac crest and costal
margin. B, The retroperitoneal tunnels are created by reﬂecting the viscera to the right and performing blunt dissection
between the right and left femoral incisions. The right retroperitoneal tunnel occurs cephalad to the bladder and allows
the limb of the graft to course in a long, gentle arc. C,Demonstration of the end-to-end proximal anastomosis of a redo
ABF bypass that frequently can be constructed in a juxtarenal location immediately above the prior repair but below the
renal arteries.
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considered signiﬁcant.
RESULTS
Patient population. During the study interval, 238
aortofemoral and 6 thoracobifemoral bypass proceduresfor AIOD were performed. Primary aortic operations for
AIOD included the following: pABF bypass, 196 cases;
aorto-unifemoral bypass, 24 cases; and thoracobifemoral
bypass, 5 cases. Eighteen patients underwent rABF bypass,
with one patient receiving thoracobifemoral bypass after
a failed ABF bypass. Median time from index ABF bypass
Table I. Patient characteristics and comorbidities
Feature
ABF
(n ¼ 19)
Redo ABF
(n ¼ 19) P value
Age, years 57.4 6 7.7 57.6 6 7.9 .8
Female 12 (63) 8 (42) .3
BMI 26.1 6 6.9 29.1 6 6.8 .2
Comorbidities
Hypertension 15 (79) 12 (63) .5
Smoking 19 (100) 18 (95) 1
Dyslipidemia 14 (74) 18 (95) .2
CAD 7 (37) 11 (58) .3
Diabetes 5 (26) 8 (42) .5
CVOD 5 (26) 6 (32) 1
COPD 4 (21) 7 (37) .5
CHF 3 (16) 2 (11) 1
Renal insufﬁciency 3 (16) 0 .2
Composite total 3.8 6 1.6 4.5 6 1.4 .1
SVS comorbidity score 3.7 6 1.3 3.9 6 1.5 .7
ABF, Aortobifemoral bypass; BMI, body mass index; CAD, coronary artery
disease; CHF, congestive heart failure; COPD, chronic obstructive pulmo-
nary disease; CVOD, cerebrovascular occlusive disease; SVS, Society for
Vascular Surgery ($8 ¼ high risk).
Categorical variables are presented as number (%) and continuous data as
mean 6 standard deviation. Mann-Whitney test for continuous and ordered
categorical variables; Fisher exact test for nominal categorical variables.
Table II. Previous vascular surgery history, indications,
and preoperative characteristics
Feature
ABF
(n ¼ 19)
Redo ABF
(n ¼ 19) P value
Previous iliac intervention 6 (32) 3 (16) .4
Prior infrainguinal bypass 0 6 (32) .02
Prior extra-anatomic bypass 0 6 (32) .02
Indication
Claudication 6 (32) 6 (32)
Rest pain 9 (47) 8 (42)
Tissue loss 4 (21) 5 (26) 1
Preprocedural variables
Urgency
Elective 12 (63) 8 (42)
Urgent 7 (37) 8 (42)
Emergent 0 3 (16) .2
Mode of admission
Elective 13 (68) 6 (32)
Hospital transfer 4 (21) 11 (58)
Emergency department 2 (11) 2 (11) .04
Right leg ABI .44 6 .2 .36 6 .27 .5
Left leg ABI .39 6 .26 .31 6 .23 .5
ABF, Aortobifemoral bypass; ABI, ankle-brachial index.
Urgent procedure is deﬁned as receiving operation within 48 hours of
admission; Emergent procedure is deﬁned as receiving operation same day as
admission. Categorical variables are presented as number (%) and contin-
uous data as mean 6 standard deviation. c2 or Fisher exact test when
appropriate.
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regarding demographics and comorbidities of the matched
cohorts of pABF and rABF bypass patients are highlighted
in Table I. By design, no signiﬁcant differences in age,
gender, body mass index, or major comorbidities were
present.
Prior operative history and indications. Previous
surgical history, indications, and mode of presentation
are depicted in Table II. The rABF bypass patients more
frequently underwent prior extra-anatomic or lower ex-
tremity bypass compared with pABF bypass patients (P ¼
.02), but no difference in prior failed endovascular iliac
intervention before the index ABF bypass (P ¼ .4) was
found. No aortoiliac endovascular interventions were
attempted after the initial failed ABF bypass before
attempted rABF bypass. Indications for rABF bypass and
pABF bypass were the same (claudication, n ¼ 6/6
[31.6%]; P ¼ 1; critical limb ischemia, n ¼ 13/13 [78.4%];
P ¼ 1). Three rABF bypass patients (15.8%) presented
with acute limb ischemia, and after initial attempts at
graft thrombectomy failed, they underwent aortic
reconstruction.
Operative procedure. Conduit choice in all patients
for both groups was a bifurcated Dacron graft. Aortic access
was more frequently by retroperitoneal exposure in the
rABF bypass group (n ¼ 13 vs n ¼ 1; P < .0001), and a
signiﬁcantly higher proportion of the rABF bypass patients
required concomitant infrainguinal bypass or intraproce-
dural adjuncts such as profundaplasty (n ¼ 14 vs n ¼ 5;
P ¼ .01). The rABF bypass patients experienced greater
blood loss (1097 6 983 mL vs 580 6 457 mL; P ¼ .02),
received more intraoperative ﬂuids (3400 6 1422 mL vs
2279 6 993 mL; P ¼ .01), and had longer overallprocedure times (408 6 102 minutes vs 270 6 48 minutes;
P < .0001). Additional intraprocedural details are summa-
rized in Table III.
POSTOPERATIVE OUTCOMES
Total ICU (days 6 standard deviation: pABF bypass,
4.6 6 3.8; rABF bypass, 3.7 6 1.4; P ¼ .9) and hospital
(days 6 standard deviation: pABF bypass, 11.2 6 10.4;
rABF bypass, 9.1 6 4.5; P ¼ .7) lengths of stay were
similar. No 30-day or in-hospital deaths occurred in either
group. Similar rates of major complications were detected
in the two groups (pABF bypass, n ¼ 6 [31.6%]; rABF
bypass, n ¼ 4 [21.1%]; observed difference in rates,
pABF  rABF ¼ 9.5%; 95% conﬁdence interval for differ-
ence in rates, 17.6% to 36.7%; P ¼ .7). No major
bleeding (return to operating room or $4 units postoper-
ative transfusion) or early graft or lower extremity ischemia
events occurred in either cohort. No perioperative renal
complications occurred in the rABF bypass subgroup,
whereas two pABF bypass patients experienced a tempo-
rary, $5% decrease in preoperative estimated glomerular
ﬁltration rate (P ¼ .5); however, both patients were at their
preoperative baseline at time of discharge or their last clinic
appointment. The 30-day clinical outcomes are displayed
in Table IV.
Six pABF bypass patients experienced a major compli-
cation postoperatively. Two had signiﬁcant dysrhythmias
requiring ICU readmission, with one ultimately receiving
a pacemaker. Two additional patients developed pulmo-
nary complications: pneumonia (one) and pleural effusion
Table III. Categorization of procedural variables after aortobifemoral (ABF) bypass
Variable ABF (n ¼ 19) Redo ABF (n ¼ 19) P value
Aortic access
Retroperitoneal 1 (5) 13 (68)
Transperitoneal 18 (95) 5 (26)
Thorax 0 1 (5) <.0001
Aortic anastomosis
End to end 8 (42) 14 (74)
End to side 11 (58) 5 (26) .01
Aortic cross-clamp position
Thorax 0 1 (5)
Supraceliac 0 2 (11)
Suprarenal 6 (32) 6 (32)
Infrarenal 13 (68) 10 (53) .4
Cross-clamp time, minutes 24.7 6 7.9 22.8 6 5.0 .8
Renal ischemia, minutes 21.0 6 3.3 24.7 6 5.7 .2
Adjunct 5 (26) 14 (74) .01
Lower extremity bypass 2 (11) 8 (42) .06
Intraoperative details
Estimated blood loss, mL 580 6 457 1097 6 983 .02
Intravenous ﬂuid, mL 2279 6 993 3400 6 1422 .01
Packed red blood cells, units 1.0 6 1.2 2.2 6 2.0 .06
Plasma, units 0.3 6 0.7 0.7 6 1.2 .3
Autotransfusion, mL 105 6 254 179 6 334 .4
Colloid, mL 289 6 356 500 6 441 .1
Procedure time, minutes 270 6 48 408 6 102 <.0001
Procedure time is deﬁned as time from incision to dressing application. Categorical variables are presented as number (%) and continuous data as mean 6
standard deviation. Mann-Whitney test for continuous variables and ordered categorical variables; Fisher exact test for nominal categorical variables when
appropriate.
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pABF bypass cohort who developed major complications
were one patient with profound electrolyte disturbances
secondary to chronic steroid use and adrenal insufﬁciency
and one patient with prolonged ileus necessitating nasogas-
tric drainage and parenteral nutrition until resolution.
Four rABF bypass patients experienced a major compli-
cation, including non-ST elevation myocardial infarction
(1), bradyarrhythmia needing temporary pacer placement
(1), and tachyarrhythmia requiring ICU readmission with
pharmacologic intervention (1). The ﬁnal patient was
treated for presumptive pneumonia after respiratory failure
and reintubation. This patient required an additional 3 days
in the ICU and eventually was discharged to a skilled
nursing facility.
MALEs. The 1- and 2-year rates for freedom from
MALEs were 93% 6 7% and 82% 6 9% vs 78% 6 8% and
78% 6 10% for pABF vs rABF bypass patients, respectively
(log-rank, P ¼ .6; Fig 3). The corresponding primary
patency of pABF bypass and rABF bypass is 76% and 78% at
24 months (log-rank, P ¼ .61; Supplementary Fig, online
only). At median follow-up of 11.9 months (range, 0.2-
42 months), four patients (21.1%) in the rABF bypass
group experienced MALEs vs three patients (15.8%) in the
pABF bypass cohort (P ¼ 1). All cases occurred in elective
patients who were managed for critical limb ischemia
(Rutherford class 4-615). Details of MALEs are summa-
rized in Table V.
Survival. Two-year amputation-free survival was
90% 6 9% vs 89% 6 8% between pABF and rABF bypasspatients (log-rank, P ¼ .5; Fig 4). Two-year survival
(6standard error mean) was 91% 6 9% and 90% 6 9%
for pABF and rABF bypass patients (log-rank, P ¼ .8)
(Fig 5).
DISCUSSION
The results of our study further establish the role of
rABF bypass grafting in patients with AIOD and highlight
that in appropriately selected patients, outcomes compara-
ble to those of pABF bypass can be achieved. Notably,
although rABF bypass had higher procedural complexity
compared with pABF bypass as evidenced by greater oper-
ative time, blood loss, and need for adjunctive procedures,
no signiﬁcant differences in perioperative morbidity or
mortality were identiﬁed. Equivalent hemodynamic im-
provement was detected as measured by ABIs, and similar
rates of MALEs occurred in both groups. Furthermore,
midterm durability of rABF bypass was consistent with
pABF bypass, and similar survival was observed. The signif-
icance of these ﬁndings is further underscored by the fact
that our study represents one of the largest published expe-
riences of rABF bypass for AIOD.
The principle reasons that ABF bypass for management
of AIOD remains the gold standard against which all other
therapies should be compared are its well-documented dura-
bility, superior functional outcomes (hemodynamic improve-
ment, symptom relief, and limb salvage), and applicability to
virtually all patterns of AIOD.17 Primary patency of ABF
bypass grafts for AIOD has been reported to be 76.6% to
95% at 5 years and 75% at 10 years.2,5,17 Postoperative
Table IV. Categorization of complications and outcomes after aortobifemoral (ABF) bypass
Outcomes ABF (n ¼ 19) Redo ABF (n ¼ 19) P value
Length of stay, days 11.2 6 10.4 9.1 6 4.5 .7
Death, 30-day and in-hospital 0 0 NA
ICU days 4.6 6 3.8 3.7 6 1.4 .9
Disposition
Home 14 (74) 12 (63)
Rehabilitation 5 (26) 6 (32)
Skilled nursing facility 0 1 (5.35) .7
Increase right ABI (d) .43 6 .51 .51 6 .25 .6
Increase left ABI (d) .50 6 .52 .50 6 .32 .8
Category
Major complication 6 (32) 4 (21) .7
Pulmonary 3 (16) 1 (5) .6
Renal 2 (11) 0 .5
Bleeding 0 0 NA
Cardiac 2 (11) 3 (16) 1
Gastrointestinal 1 (5) 1 (5) 1
Wound 2 (11) 3 (16) .3
Urinary tract infection 1 (5) 2 (11) 1
Total number of complications 0.6 6 1.1 0.7 6 0.8 .3
ABI (d), Ankle-brachial index change/delta from preoperative baseline value; ICU, intensive care unit; NA, not applicable.
Categorical variables are presented as number (%) and continuous data as mean6 standard deviation. Mann-Whitney test for continuous variables and ordered
categorical variables; Fisher exact test for nominal categorical variables when appropriate.
Fig 3. The freedom from major adverse limb events (MALEs; any
graft thrombosis, revision, or amputation) after primary and redo
aortobifemoral (ABF) bypass. All demonstrated intervals are <10%
standard error mean.
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mortality in the elective setting for appropriately selected
patients.6,9,18 Indeed, our results are consistent with the liter-
ature and further support a role for rABF bypass grafting.
The predominant etiology of ABF bypass failures is
attributed to problems at the femoral anastomosis,
including development of neointimal hyperplasia, pseudo-
aneurysms, and progression of infrainguinal occlusive
disease.2,19 Unilateral limb complications are traditionally
managed with thrombectomy, femoral anastomotic revi-
sion or interposition grafting, femorofemoral bypass, or
axillofemoral bypass.20 Interestingly, similar complications
involving the aortic anastomosis leading to graft failure
are less frequent, ranging between 0.2% and 27% at 15 yearsby life-table estimates, with most series focusing on aneu-
rysmal and pseudoaneurysmal disease.21-23
Series focusing on reoperative aortic surgery after failed
ABF bypass grafting for AIOD have relatively few cases of
rABF bypass for a thrombosed graft. The heterogeneous
nature of the reports describing reoperative strategies after
failed ABF bypass makes it difﬁcult to determine the “true”
perioperative outcomes of rABF bypass grafting. Among
1520 aortic procedures performed during 29 years by
Kraus et al,21 36 aortic reoperations were performed, and
only six of these patients underwent rABF bypass for graft
thrombosis. Of 329 consecutive aortic procedures per-
formed during a 5-year period, Hagino et al24 described
11 aortic reoperations for proximal anastomotic failure
and commented that proximal aortic graft complications
are difﬁcult to repair and associated with signiﬁcant
morbidity (27%). Tapper et al25 described 19 patients
with occluded ABF bypass grafts, and eight underwent
rABF bypass. Notably, one rABF bypass patient had unrec-
ognized ureteral injury that ultimately required a nephrec-
tomy, and two major amputations occurred in the rABF
bypass subgroup after hospital discharge. The two major
amputations occurred in patients presenting with acute
aortic occlusion, so the outcome was likely dictated by
the clinical presentation and not the remedial choice of
rABF bypass. Their conclusions were that rABF bypass
was useful in selected patients who had surgically correct-
able lesions, such as anastomotic stricture, native aortic
atherosclerotic disease below the renal arteries (but above
the pABF bypass), redundant graft, or identiﬁable distal
anastomotic disease.25,26
There are few indications for direct, redo aortic recon-
struction for AIOD, and the absolute numbers performed
at most large medical centers annually are relatively small.
Table V. Major adverse limb events (MALEs) after aortobifemoral (ABF) bypass
Initial
indication Event Reintervention
Time to MALE,
months Eventual outcome
Primary ABF
Patient 1, 49 F CLI Rutherford 5 Right limb thrombosis Revision distal bypass 10.2 AKA at 11.5 months
Left limb thrombosis Revision distal bypass 15.3 AKA at 23.1 months
Patient 2, 65 F CLI Rutherford 4 Right limb thrombosis Thrombectomy distal bypass 9.8 Patent graft
Patient 3, 57 M CLI Rutherford 5 Infected LEB Excision LEB 3.1 Patent graft
Redo ABF
Patient 1, 46 M CLI Rutherford 5 Thrombosis LEB None 2.9 AKA at 3.1 months
Patient 2, 68 M CLI Rutherford 6 Progression gangrene None 0.1 BKA at 0.1 month
Patient 3, 41 F CLI Rutherford 4 New digital gangrene Autogenous LEB 1.4 Patent graft
Patient 4, 5 1F CLI, Rutherford 5 Failing LEB PTA of SFA 4.1 Patent graft
AKA, Above-knee amputation; BKA, below-knee amputation; CLI, critical limb ischemia; LEB, lower extremity bypass; PTA, percutaneous transluminal
angioplasty; SFA, superﬁcial femoral artery.
Fig 4. The amputation-free survival after primary and redo aor-
tobifemoral (ABF) bypass. Standard error mean is <10% up to
24 months.
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represented only 7.8% (19 of 244) of the open aortic cases
for AIOD during an 11-year period. Patient selection and
preoperative planning for rABF bypass are weighted on
multiple factors, including comorbidity severity and
anatomic distribution of disease. Several remedial strategies
can be employed to address a failed ABF bypass, and the
mode of presentation initiates a treatment algorithm
(Fig 1) that spans a spectrum of interventions from medical
therapy to extra-anatomic revascularization to redo aortic
operations. Younger, less comorbid patients with progres-
sive occlusive disease in the infrarenal segment of the aorta
above the initial proximal anastomosis and those with
repeated limb failures without an identiﬁable lesion in the
outﬂow vessels represent a subset of patients who are prob-
ably best managed with direct, redo aortoiliac revasculari-
zation. Indeed, in this current series, the average age
(57.6 6 7.9 years) and SVS comorbidity score (3.9 6
1.5) are consistent with this bias. Another important
consideration for operative planning is conduit choice,
which can be inﬂuenced by patient age, donor or recipient
vessel diameters, and underlying mechanism of failure (eg,
hypercoagulable syndrome). Our series used prosthetic
graft for all ABF bypass operations; however, Jackson
et al27 have demonstrated that autogenous femoral-
popliteal vein may be superior in patients with premature
atherosclerotic disease (eg, age <55 years).
The conduct of rABF bypass is technically more
demanding compared with pABF bypass. Three elements
of the procedure present the most challenge: the groin
dissection, the aortic dissection, and the tunnel creation.
Whereas repeated groin operations are familiar in contem-
porary practice, extensive dissection of the profunda femo-
ris artery is often required, and there is frequent need for
concomitant infrainguinal bypass, particularly in cases of
ischemic tissue loss. Notably, 42.1% (n ¼ 8) of the rABF
bypass patients underwent lower extremity bypass
compared with only 10.5% (n ¼ 2) in the pABF bypass
group (P ¼ .06). In our experience, the perirenal aortic
dissection planes are often undisturbed, despite the redo
nature of the operation, because the original anastomosiswas inappropriately constructed too caudal on the aorta.
In cases in which the original anastomosis was sited at
the correct juxtarenal location, our preferential use of
retroperitoneal access makes the dissection in this region
relatively straightforward. Perhaps the most challenging
and anxiety-provoking component of rABF bypass when
it is performed by the transperitoneal approach is construc-
tion of the tunnels for the limbs. The ureters are often
densely adherent to the ﬁbrous capsule around the pABF
bypass limbs, making identiﬁcation difﬁcult. It is sometimes
possible to dissect the capsule away from the graft and gain
access to the original tunnels; however, this can be tedious
and dangerous, with reports of obstructive uropathy or
ureteral injury being described after transperitoneal rABF
bypass.28 Our evolution to preferential use of a retroperito-
neal approach obviates concerns about tunnel creation and
potential ureteral injury. The left limb simply passes
through the large retroperitoneal space created by rotating
the viscera, and the right limb is passed in the preperitoneal
Fig 5. The midterm survival after primary and redo aortobife-
moral (ABF) bypass. Standard error mean is <10% up to
24 months.
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femoral vessels (Fig 2, B). To date, this graft conﬁguration
has worked well for us, and no rABF bypass limb occlusions
have occurred.
The demanding nature of rABF bypass has led to
reports of different approaches to deal with a failed ABF
bypass. The most common remedial strategy is an extra-
anatomic conﬁguration, such as axillofemoral bypass.29
Operative mortality rates for extra-anatomic bypass might
be expected to be better than those for ABF bypass because
of the extracavitary nature of these procedures and the fact
that aortic cross-clamping is not required during the oper-
ation. However, an operative mortality rate of 0% to 4% for
femorofemoral bypass and 2% to 11% for axillobifemoral
bypass is a reﬂection of the selected patients in whom these
procedures are performed.20,29 Five-year primary patency
of extra-anatomic bypasses performed for AIOD ranges
from 19% to 50% for axillobifemoral bypass and 44% to
85% for femoral-femoral bypass.20,29 These operations are
inferior to direct, primary (or secondary) aortic reconstruc-
tion, so we reserve them for older patients with extensive
comorbidities and short life expectancy.
An alternative aortic reoperation to rABF bypass is
thoracobifemoral bypass, which has comparable magnitude
and outcomes to pABF bypass.30,31 This operation has
technical demands similar to those of rABF bypass, but
our enthusiasm for this approach is muted by three factors:
(1) thoracic aortic cross-clamp potentially places the spinal
cord at risk; (2) remedial options for an infected graft are
poor; (3) prevalence of smoking or chronic obstructive pul-
monary disease history and need for thoracotomy leading
to postoperative pulmonary morbidity. We readily concede
that these complications are rare; however, we submit that
the “true” rate of complications from any of the repeated
aortic operations for AIOD is poorly understood because
of the limited published experience. Thoracobifemoralbypass is most often used as a tertiary option in our practice
(initial operation, ABF bypass; second operation, rABF
bypass; third operation, neoaortoiliac system if enough
residual perirenal aorta is present to construct an anasto-
mosis or thoracobifemoral bypass). Other scenarios in
which we have used this procedure are in patients with sig-
niﬁcant visceral aortic occlusive disease in whom an infrare-
nal anastomosis is not possible and in cases of multiple
failed axillofemoral bypass grafts performed after aortic
ligation for graft infection.
The current study has several limitations inherent to its
retrospective case-control design. Propensity matching was
not performed. The patients had extensive selection bias
based on multiple physiologic, anatomic, and comorbid
factors. The small sample size and lack of comparison to
alternative remedial strategies make deﬁnitive conclusions
and comparisons difﬁcult to make. The risk of type II error
from this analysis cannot be overstated, and it is possible
that results of rABF bypass are worse than the outcomes
reported in our experience. The limited follow-up time
does not allow any insight into the long-term durability
or reintervention risk of the procedure. This issue is partic-
ularly important in a patient population that frequently has
more advanced AIOD disease burden compared with
pABF bypass patients.
CONCLUSIONS
The rABF bypass for AIOD is a technically demanding
operation; however, it can be performed safely with short-
and midterm outcomes comparable to those of pABF
bypass in selected patients. Greater patient numbers and
longer term follow-up are needed to further deﬁne the
role of rABF bypass.
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mary and redo aortobifemoral (ABF) bypass. Standard error mean
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